|
Campus Biotech Innovation Park now hosts 23 startups, 7 foundations, 3 VCs, 13 support organisations, as well as UNIGE, EPFL Extension School and the Geneva Tsinghua Initiative –in the SDGs Solution Space.
CBIP startups are thriving:
ABCDx has been granted EUR 2.4M by Eurostars Funding Programme for the development of their rapid test for acute stroke brain biomarkers, which can be used in the ambulance. Faster stroke diagnosis, as well as time to treat, will increase patient survival rate and improve outcomes.
ABCDx will work with Precision Biosensor, an innovative point-of-care test manufacturer and Seoul St. Mary’s Hospital in South Korea. Read more
Artiria Medical aims to prevent arterial constriction following hemorrhagic stroke. The early-stage medical device company recently joined forces with the Wyss Center, a non-profit organization dedicated to bringing state-of-the-art therapies to the patient. More information can be found here.
Earlysight is developing a medical device to help doctors detect and treat eye diseases at an early-stage by using precise retinal imaging. This summer, the startup secured CHF 2.3 million led by Verve Ventures to support its growth journey leading to market entry. EarlySight has received support from VentureKick, FIT “Fondation pour l’innovation technologique”, and was one of the EIT Health Headstart awardees. Read more
MaxiVAX is a clinical stage (Phase II) biotech company dedicated to the cure of cancer by immunotherapy. In collaboration with a research team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE), they developed an innovative technology called “cell encapsulation.” COVID-19 pandemic has motivated the scientists to broaden the scope of their technology, which was was developed to stimulate immunity to fight cancer, to test its effectiveness against viruses. Read more
iOnctura is a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface. They recently won the support of Innosuisse in a 2-year innovation project. The Innosuisse grant of CHF 600k will fund fifty percent of the project’s costs, covering the research carried out by Professor Francesco Bertoni of the Institute of Oncology Research (IOR) in Bellinzona, Switzerland. Find out about the first volunteer here
|
